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emtricitabine (RPV/TDF/FTC) in treatment-experienced patients
infected with HIV-1
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St Stephens Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Purpose of the study
Rilpivirine (RPV) is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown non-inferiority to efavirenz
(EFV) in terms of efficacy and safety profiles. The vast majority of clinical data has been performed in the treatment naı ¨ve
population and has not been studied in depth in treatment-experienced patients.We sought to explore the safety and efficacy of
RPV/TDF/FTC in treatment-experienced patients attending our clinics.
Methods
HIV-infected individuals commenced on RPV/TDF/FTC from December 2011 to June 2012 were retrospectively identified from a
patient database. Patient demographics were extracted. Biochemical, virological and immunological parameters were collated.
At baseline, 1 month and 3 month time points the following laboratory results were compared using the Kruskal-Wallis test: CD4
count, HIV viral load, amino transferase (ALT), cholesterol, triglyceride and HDL/cholesterol ratio.
Summary of results
Sixty-five patients (4 female) were identified. Median age was 38 years (range: 2573). Fifty-six patients were treatment
experienced (2 re-start); 39 on NNRTI-based (33 on EFV), 10 on PI-based and 4 on other regimens. 9 patients were naı ¨ve to
treatment. The reasons for switch are illustrated in Fig. 1.
Fifty-four patients had HIV-RNA-1B40 copies/mL at the time of switch and all remained undetectable at 3 months. At
baseline, the median CD4 count was 555 cells/mm
3 (range: 2091586) in the switch group, which increased significantly to 638
cells/mm
3 (pB0.005) 3 months after switch. Switch to RPV/TDF/FTC had a favorable effect on lipid profile. At baseline the
median cholesterol, triglyceride and HDL/cholesterol ratio levels were 4.8 mmol/L, 1.78 mmol/L and 4.37 respectively. At 1
month post-switch this decreased to 4.5 mmol/L, 1.65 mmol/L and 4.24 and at 3 months post-switch decreased to 4.1 mmol/L,
1.44 mmol/L and 4.04. Median HIV-RNA-1 in treatment-naı ¨ve patients (n9) at baseline was 50298 copies/mL, at 1 month four
patients had HIV-RNA-1B40 copies/mL and at 3 months eight patients had HIV-RNA-1B40 copies/mL. RPV/TDF/FTC had no
favourable effect on lipid profile in treatment-naı ¨ve group and had no effect on ALT levels in either the switch or the treatment-
naı ¨ve group.
Conclusion
In this cohort, RPV/TDF/FTC has been shown to have a safe virological efficacy and safety profile as a switch therapy for patients
suppressed on their current standard of care and are experiencing adverse events.
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